ADAP Quote, Trading Chart, Adaptimmune Therapeutics plc
home / stock / adap / adap quote
$1.52 Last:
4.11% Change Percent:
$1.5 Open:
$1.52 Previous Close:
$1.54 High:
$1.4 Low:
248,080 Volume:
05/27/2022 04:53:21 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
ADAP Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2022-05-27 | 1.5 | 1.52 | 1.54 | 1.4 | 248,080 |
| 2022-05-26 | 1.45 | 1.46 | 1.49 | 1.43 | 225,226 |
| 2022-05-25 | 1.54 | 1.48 | 1.5658 | 1.42 | 215,026 |
| 2022-05-24 | 1.53 | 1.47 | 1.53 | 1.425 | 255,162 |
| 2022-05-23 | 1.64 | 1.51 | 1.65 | 1.5 | 307,749 |
| 2022-05-20 | 1.73 | 1.64 | 1.76 | 1.5494 | 263,161 |
| 2022-05-19 | 1.45 | 1.67 | 1.79 | 1.43 | 785,367 |
| 2022-05-18 | 1.56 | 1.47 | 1.56 | 1.4591 | 121,804 |
| 2022-05-17 | 1.52 | 1.57 | 1.61 | 1.455 | 377,374 |
| 2022-05-16 | 1.4 | 1.42 | 1.48 | 1.37 | 193,996 |
| 2022-05-13 | 1.37 | 1.41 | 1.46 | 1.35 | 271,754 |
| 2022-05-12 | 1.33 | 1.35 | 1.425 | 1.26 | 707,816 |
| 2022-05-11 | 1.53 | 1.33 | 1.54 | 1.33 | 618,524 |
| 2022-05-10 | 1.56 | 1.56 | 1.64 | 1.48 | 543,702 |
| 2022-05-09 | 1.75 | 1.54 | 1.97 | 1.5 | 823,966 |
| 2022-05-06 | 1.75 | 1.71 | 1.78 | 1.645 | 1,103,373 |
| 2022-05-05 | 1.9 | 1.78 | 1.91 | 1.77 | 190,490 |
| 2022-05-04 | 1.85 | 1.91 | 1.92 | 1.76 | 357,737 |
| 2022-05-03 | 1.9 | 1.82 | 1.905 | 1.81 | 208,832 |
| 2022-05-02 | 1.7 | 1.87 | 1.87 | 1.7 | 348,853 |
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
-
- Patients who responded to afami-cel had longer progression-free survival (median 58 weeks) compared to non-responders (median 12 weeks) - - Responses occurred across subgroups, with greater response rates associated with lower baseline tumor burden, fewer prior lines of therapy, and higher ...
-
Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) , a clinical-stage biopharmaceutical company that specializes in T-cell therapies to treat cancer, jumped 13.4% on Tuesday. The company's shares are down more than 58% so far this year. The company reported positive proof-of-...
-
- New next-gen SPEAR T-cells (ADP-A2M4N7X19) designed to enhance depth and durability of clinical response demonstrated enhanced proliferation, survival, and recruitment of immune cells in vitro - - Engineered TILs (ADP-TILIL7) intended to improve clinical responses, produced levels o...